BACKGROUND Chronic hepatitis B consists of different clinical phases. Laboratory and histological assessments can help differentiate the clinical phases of this disease and thus lead to better management. OBJECTIVES This study was conducted to determine laboratory and histological characteristics of HBeAg-negative and HBeAg-positive chronic hepatitis B patients. PATIENTS AND METHODS In this...

Chronic infection with the hepatitis B virus has been linked epidemiologically to the development of hepatocellular carcinoma for more than 30 years. Although the mechanisms by which chronic hepatitis B viral infection results in hepatocellular carcinoma are unclear, there is good evidence that the virus itself exerts a direct hepatocarcinogenic effect, and this has implications for prevention....

BACKGROUND Nucleoside analogues such as lamivudine for chronic hepatitis B have an excellent safety profile while patients are on therapy but reactivation flares occur in 19-50% of patients after stopping therapy, some of whom develop liver decompensation. AIMS To describe and report three cases who developed fatal hepatitis B reactivation after stopping nucleoside analogue therapy. SUBJECT...

Today, chronic viral hepatitis is considered as a public health problem in the world. Totally, 5% of the world population, especially in Asia and Africa suffer from this problem. The prevalence of acute hepatitis in America is 0.1-0.2 percent, 50% of those with hepatitis C (HCV) and 5-10% of them with hepatitis B (HCV) develop chronic hepatitis. Determining HBV and HCV genotypes is important to...

OBJECTIVE To study the role of hepatitis B virus with A1762T/G1764A double mutation in liver cirrhosis and hepatocellular carcinoma, and create a sensitive, fast, accurate assay for detection of A1762T/G1764A double mutation. METHODS We developed an accurate and fast real-time amplification refractory mutation system to detect A1762T/G1764A double mutation. Cloned hepatitis B virus genome was...

The essential role of multispecific immune responses for the control of hepatitis B virus (HBV) infection implies the need of multimodal therapeutic strategies for chronic HBV infection, including antiviral chemotherapy and immunomodulation. This hypothesis was tested in the woodchuck model by a combination of lamivudine pretreatment and subsequent immunizations of woodchucks chronically infect...

background and objective: presence of hepatitis b core antibody (anti-hbc) in the absence of hepatitis b surface antigen (hbsag) and hepatitis b surface antibody (anti-hbs) is defined, as isolated anti-hbc. little is known about the clinical significance of the isolated anti-hbc in hepatitis b virus (hbv) infections. the aim of this study was to assess the significance of anti-hbc as the only m...

BACKGROUND Hepatitis B infections, characterized by the presence of a viral genome without detectable hepatitis B surface antigen (HBsAg; Occult hepatitis B infection [OBI]), have been reported recently. OBJECTIVES We performed serological and molecular characterization of OBI among blood donors at Jiangsu province blood center during years 2013 and 2014. METHODS All donor samples were rout...

conclusions treatment with peg ifn α achieved a sustained negativity of hdv rna in about one third of patients. duration of peg ifn α therapy might be prolonged to at least 24 months or more to prevent the occurrence of hepatitis b virus (hbv) relapse encountered six months after completion of the treatment. patients and methods the sample size was based on available patients potentially to be ...